Dados B3 › FASA3 × CSAN3
FASA3 × CSAN3
Indicators
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | FASA3 | CSAN3 | year |
|---|---|---|---|
| ROE | 0.0%! | -120.0% | 2025 |
| ROIC | -70.7%! | -0.2%! | 2025 |
| ROA | -57.3%! | -7.4% | 2025 |
| Gross margin | -3.6% | 32.6% | 2025 |
| EBIT margin | -29.8% | -0.5% | 2025 |
| Net margin | -30.4% | -25.2% | 2025 |
| Net debt/EBITDA | -2.46x | 3.97x | 2022 |
| Current ratio | 1.39x | 2.58x | 2025 |
| Revenue growth (1y) | -100.0%! | 11.4% | 2024 |
| Revenue growth (5y CAGR) | 20.1% | 24.5% | 2025 |
| Piotroski F-Score | 4/9! | 4/9 | 2025 |
Point-in-time multiples
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | FASA3 | CSAN3 | year |
|---|---|---|---|
| P/E | — | -2.34x | 2025 |
| P/B | 0.25x | 4.28x | 2025 |
| EV/EBITDA | — | 17.91x | 2025 |
| FCF yield | -261.4% | 20.1% | 2025 |
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 07:26 UTC. If this does not match /saude, you are reading a cached copy.
Sources: CVM (open data, ODbL) and B3 (COTAHIST). Not affiliated with B3 or the CVM. Not investment advice.
Numbers on this page are live. Data version 2026-09-27-reapresentacao-agreg · page generated 2026-09-27 07:26 UTC. If this does not match /saude, you are reading a cached copy.